Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer

Next Previous
Search
Trial Profile

A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sapanisertib (Primary)
  • Indications Thyroid cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 15 Dec 2023 According to ClinicalTrials.gov record, protocol has been amended to change the primary endpoints of the study and hence the overall trial focus has also been changed to AR and TU. The phase of the trial was also changed to Phase I/II.
    • 15 Dec 2023 Status changed from active, no longer recruiting to completed.
    • 18 Feb 2022 Planned End Date changed from 1 Jan 2022 to 1 Dec 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top